Clinical trial NCT04060394: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Official title: A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Metastatic Castration-resistant Prostate Cancer
Lead sponsor: Laekna Limited
Sponsor class: INDUSTRY
First posted: 2019-08-19
Enrollment: 49
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Phase 1 Dose Escalation to determine Recommended Phase II Dose (RP2D) of LAE001/Prednisone plus Afuresertib in m-CRPC patients. Once RP2D is determined, Phase II will evaluate LAE001/Prednisone plus Afuresertib vs and Docetaxel/Prednisone plus Afuresertib in m-CRPC patients.
Primary purpose: TREATMENT

Brief summary: The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC) patients who have progressed/drug resistant following prior standard care treatments of any anti-androgen. This study intends to identify the most appropriate combined doses of LAE001/prednisone and afuresertib in m-CRPC patients who have progressive disease or are intolerant of 2 prior standard treatments of any anti-androgen or anti-androgen treatment plus chemotherapy.

Detailed description: The Phase I part of this study will perform a dose-escalation to identify the recommended Phase II dose of LAE001/prednisone plus afuresertib in m-CRPC patients.

In the Phase II part of this study, the anti-tumor efficacy of LAE001/prednisone plus afuresertib and docetaxel/prednisone plus afuresertib will be assessed in mCRPC patients with PTEN loss and/or PIK3CA/AKT/PTEN alteration who have progressed on, or who are intolerant of, 1-3 prior standard treatments for mCSPC, or nmCRPC, or mCRPC, including at least one antiandrogen treatment and no more than one chemotherapy. Participants will be assigned to one of the two study cohorts, based on the investigator's clinical judgement. Cohort 1 will receive LAE001/prednisone plus afuresertib using RP2D established in the Phase I study. Cohort 2 will receive docetaxel/prednisone plus afuresertib, with a safety run-in period during the first cycle in the first 6 patients. These study results will provide preliminary efficacy and safety information of the combination of LAE001/prednisone plus afuresertib and docetaxel/prednisone plus afuresertib as requested in the Food and Drug Administration (FDA) combined therapy guideline. Whether to move one or both combination therapies to the pivotal study will be based on the PFS improvements of the combination therapy versus historical controls of abiraterone or docetaxel monotherapies in mCRPC patients who failed 1-3 lines of standard of care therapies.

Eligibility criteria: Inclusion Criteria:

1. Patients, males ≥18 years of age, must be able to provide written informed consent.
2. Patients must have documented histological or cytological evidence of adenocarcinoma of the prostate (excluding neuroendocrine differentiation or small cell histology).
3. Patients must have radiographic evidence of metastatic disease for mCRPC based on the 'Guideline of American Urological Association for Prostate Cancer' before study enrollment. (https://www.auanet.org/guidelines/prostate-cancer-castration-resistant11 guideline)
4. For PTEN and PIK3CA/AKT status test:

   Phase I: The PTEN/PIK3CA/AKT status test is optional and the result could be either positive, negative, undetermined or invalid. Phase II: Patients will be allowed to enroll regardless of the biomarker status, medical monitor review is necessary before enrollment. The biomarker status tests will be performed with the following order. The biomarker results of all enrolled patients will be used for retrospective analysis purposes.
   * Patients that have a documentation of "PTEN LOSS" and/or PTEN/PIK3CA/AKT alteration from a previous test on either tissue or liquid biopsy (e.g., IHC or next generation sequencing NGS), no further biomarker tests are needed in this study.
   * Patients who have PTEN or PI3KPIK3CA/AKT alteration status reported other than "PTEN LOSS", "PIK3CA/AKT alterations" or never completed any PTEN/PIK3CA/AKT test before, could either provide the archival tumor samples collected at any time before study enrollment or do a fresh core tumor biopsy.
   * As the last option, patients can perform a liquid biopsy for PTEN LOSS and PTEN/PIK3CA/AKT alteration tests by NGS of cfDNA if they have no archival tissue to provide, no tumor lesion for biopsy or a fresh biopsy is not feasible.
5. Patients must have progressive disease based on the PCWG3 criteria:

   * Patients who progressed based solely on total PSA rising, should have had a sequence of rising values on 3 consecutive occasions of at least 1-week intervals (if the third measurement is not greater than the second measurement, a fourth measurement at least a week apart must be taken and must be greater than the second measurement) and should have 2.0 ng/mL minimum level for entry. Note: Patient must have had a prior PSA response, followed by documented PSA progression on prior hormone treatment.
   * Patients who have documented disease progression per RECIST 1.1 are eligible independent of PSA.
   * Patients with bone only progression according to PCWG3 (i.e., bone scan showing

   appearance of ≥2 new lesions).
6. Patients must have castration levels of testosterone (\<50 ng/dL or 1.7 nmol/L). Note: Patients must have undergone androgen deprivation therapy (ADT), such as orchiectomy, or have been on luteinizing hormone releasing hormone (LHRH) agonists or antagonists, for at least 3 months prior to study enrollment. Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study.
7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
8. Patients must have adequate hematopoietic function by local laboratory within the 28 days before enrollment, as evidenced by:

   * Absolute neutrophil count ≥1,500/μL
   * Platelet count ≥75,000/μL
   * Hemoglobin ≥9 g/dL
9. Note: Criteria must be met without growth factors or transfusion within 10 days prior to the screening lab tests. Total serum bilirubin ≤1.5 × ULN within the 28 days before enrollment (in patients with known Gilbert's syndrome, total bilirubin ≤3 × ULN with direct bilirubin ≤1.5 × ULN).
10. Aspartate aminotransferase and alanine aminotransferase ≤2.5 × ULN except for patients with tumor involvement of the liver who must have AST and ALT ≤5 × ULN within the 28 days before enrollment.
11. Patients must have adequate renal function as evidenced by a serum creatinine of

    ≤1.5 × ULN for the reference laboratory or creatinine clearance ≥30 mL/min within the 28 days before enrollment (calculated from Cockcroft-Gault formula or 24-hour urine collection).
12. Serum potassium ≥3.5 mmol/L and \< ULN within the 28 days before enrollment.
13. Fasting plasma glucose (fasting is defined as no caloric intake for at least 8 hours):

    * ≤126 mg/dL for those patients without a pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus
    * ≤167 mg/dL for those patients with a pre-existing diagnosis of Type 2 diabetes mellitus AND glycosylated haemoglobin (HbA1C) ≤8%
14. Phase I: Patients who have mCRPC progressed or are intolerant after receiving at least 1 prior treatments of any anti-androgen (such as abiraterone, enzalutamide, apalutamide, or any other AR antagonists that are approved later), and/or chemotherapy. Patients must have at least 3 weeks of treatment of any antiandrogen and/or completed at least 4 Cycles of docetaxel or cabazitaxel treatment before their screening visit.

    Phase II: Patients who have mCRPC progressed or are intolerant after receiving 1-3 prior standard treatments for mCSPC, or nmCRPC, or mCRPC, including at least one second-generation antiandrogen treatment (i.e., abiraterone, enzalutamide, apalutamide, or darolutamide), and no more than one chemotherapy. Patients must have at least 3 weeks of treatment of any antiandrogen and/or completed at least 3 Cycles of docetaxel or cabazitaxel treatment and/or at least 3 injections of R223 and/or at least 2 injections of sipuleucel-T to be counted as one prior therapy. Patient's current diagnosis at screening must be mCRPC.
15. Concomitant use of bisphosphonates and other bone supportive agents is allowed if the dose and renal function have been stable for at least 12 weeks before enrollment and no related ≥Grade 2 side effects are present for at least 4 weeks prior to study drug treatment. The minimum washout period is 4 weeks for prostate cancer therapy (cytotoxic, biologics, antiandrogens, etc.) before enrollment, starting from the day the therapies were stopped.
16. Patients with a female partner of childbearing potential must agree to use condoms plus an additional contraceptive method to avoid conception until the end of relevant systemic exposure plus 90 days following the Clinical Trial Facilitation Group contraception guideline from September 2014.
17. Patient should be suitable for oral medication and should not have any known gastrointestinal diseases that may interfere with drug absorption.
18. Life expectancy of at least 6 months.

Exclusion Criteria:

1. Major surgery within 28 days before study treatment and/or have not adequately (Grade 1) recovered from the adverse effects of any major surgical procedures before study treatment.
2. Patients that received other second-line ADT (including but not limited to ketoconazole and amino glutethimide) within 6 weeks before enrollment.
3. Patients who have completed sipuleucel-T (Provenge®) treatment within 6 weeks of enrollment.
4. Patients who have received antiandrogens such as flutamide (EULEXIN®), bicalutamide (CASODEX®), or nilutamide (NILANDRON®) for \>3 months must be off treatment for 6 weeks prior to enrollment and should demonstrate a continued rise in PSA after withdrawal.
5. Patients who have received Radium Ra 223 dichloride (XOFIGO®) must be off therapy for 7 weeks prior to enrollment or Samarium Sm 153 lexidronam (QUADRAMET®) must be off therapy for at least 2 weeks prior to enrollment.
6. Patients that are currently receiving increasing or chronic treatment (\>5 days) with corticosteroids or another immunosuppressive agent, other than the following: daily use of up to 10 mg prednisone (or equivalent) or low-dose steroid for the control of nausea and vomiting, topical steroid, or inhaled steroid use.
7. Patients who require potassium-wasting diuretics.
8. Patients who have received any investigational agent beyond those indicated for the treatment of prostate cancer within 5 half-lives of the agent; if the half-life of the agent is not known, the patients must be off investigational therapy for 4 weeks prior to enrollment (whichever is shorter of the two should be preferred).
9. Patients who have received palliative and other radiotherapy for the target lesion within 4 weeks of study enrollment.
10. Patients with symptomatic or known central nervous system metastases from prostate cancer or who are at high risk for spinal cord compression, per investigator's judgment.
11. Patients with a history of hypothalamus, pituitary or adrenal insufficiency.
12. Patients with \>grade 2 neuropathy at study enrollment.
13. History of another primary malignancy that is currently clinically significant or currently requires active intervention.
14. Inadequately controlled hypertension (eg, systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg) or hypotension (eg, systolic blood pressure ≤ 80 mmHg or diastolic blood pressure ≤50 mmHg) after up to 3 measurements with at least 5 minutes apart during 28 days before study enrollment.
15. Patients with active cardiac disease or a history of cardiac dysfunction including any of the following:

    * Severe or unstable angina pectoris or acute coronary syndrome or stroke within 6 months prior to study enrollment.
    * Symptomatic pericarditis.
    * Documented myocardial infarction or arterial thrombotic events within 6 months prior to study enrollment.
    * History of documented congestive heart failure (New York Health Association functional classification III to IV).
    * Documented history of cardiomyopathy.
    * Known left ventricular ejection fraction \<50% as determined by multiple gated acquisition scan or echocardiogram within 28 days prior to enrollment.
    * History of clinically significant cardiac arrhythmias unsuitable to participate, as determined by the investigator.
16. Patients with a Fridericia-corrected QT (QTcF) interval of \>470 msec on the screening ECG (using the QTcF formula), has a short/long QT syndrome, or history of QT prolongation/Torsades de Pointes, unless prolonged QTc interval is due to (right or left) bundle branch block and/or pacemaker rhythm. If wide QRS complex is present, cardiology consultation is required to assess the risk for Torsade de Pointes.
17. Patients with a history of an active infection (viral, bacterial, or fungal) requiring systemic therapy within 10 days before enrollment, including but not limited to tuberculosis.
18. Patients who have active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infections.
19. Patients that are currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP1A (including but not limited:

    α-Naphthoflavone, Furafylline, Omeprazole, Lansoprazole) and isoenzyme CYP3A (including but not limited: Itraconazole, Ketoconazole, Azamulin, Troleandomycin, Verapamil, Rifampicin). The patients must have discontinued moderate or strong inducers for at least 2 weeks prior to study enrollment and must have discontinued moderate or strong inhibitors for at least 1 week before study enrollment. Spironolactone Strong bile salt export pump (BSEP) inhibitors, grapefruit juice, herbal medicines such as St. John's wort, Kava, ephedra, gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto and ginseng should be discontinued.
20. Sexually active males not willing to use a condom during the whole course of the study and for 16 weeks after stopping treatment. Male patients must not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via seminal fluid.
21. Patients with any other medical, psychiatric, or social condition, including substance abuse, which in the opinion of the investigator, would preclude participation in the study.
22. Patients with a history of upper gastrointestinal bleeding or uncontrolled peptic disease in the previous 3 months which in Investigator's opinion may impact patient's participation in the study.
23. Patients have previously received AKT or PI3 kinase pathway or mTOR inhibitors

Primary outcomes:
measure: Phase II: Radiological progression free survival (rPFS) based on change in tumor per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase I: Demonstrate safety and tolerability of LAE001/prednisone and afuresertib as combination therapy.
timeFrame: Through study completion for an average of 12 months
measure: Phase II: Radiological progression free survival (rPFS) based changes per Prostate Cancer Working Group 3 (PCWG3)
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
Secondary outcomes:
measure: Phase II: Overall Response Rate (ORR) based tumor changes per RECIST 1.1
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase II: Overall Response Rate (ORR) based tumor changes per PCWG3
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase II: Duration of Response (DOR) based on tumor changes per RECIST 1.1
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase I: Duration of Response (DOR) based on tumor changes per RECIST 1.1
timeFrame: At the end of the 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment
measure: Phase II: Duration of Response (DOR) based on tumor changes per PCWG3
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase I: Duration of Response (DOR) based on tumor changes per PCWG3
timeFrame: At the end of the 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment
measure: Phase II: Disease Control Rate (DCR) based on tumor changes per RECIST 1.1
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase II: Disease Control Rate (DCR) based on tumor changes per PCWG3
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase II: Overall Survival (OS)
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase II: Changes in Prostate Specific Antigen (PSA) levels
timeFrame: End of Treatment as compared to baseline
measure: Phase I: Changes in Prostate Specific Antigen (PSA) levels
timeFrame: Day 1 Cycle 2 (each cycle is 28 days) and all subsequent cycle and End of Treatment for an avergae of 12 months as compared to baseline
measure: Phase II: PSA response
timeFrame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
measure: Phase I: PSA response
timeFrame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
measure: Phase I: Secondary PSA response
timeFrame: Baseline to>/=12 weeks after study treatment; confirmed 4 weeks later
measure: Phase II: Best PSA response
timeFrame: Through study completion for an avergae of 12 months
measure: Phase I: Best PSA response
timeFrame: Through study completion for an average of 12 months
measure: Phase II: Time to PSA progression
timeFrame: Through study completion for an average of 12 months
measure: Phase I: Time to PSA progression
timeFrame: Through study completion for an average of 12 months
measure: Phase II: % patients with PSA progression or death from any cause
timeFrame: At 12 weeks from start of study treatment
measure: Phase II: Frequency and severity of AEs
timeFrame: Through study completion for an average of 12 months
measure: Phase I: Evaluate PK characteristics of study drug in combination treatment
timeFrame: Cycle 1 (each cycle is 28 days) Day 1 and Cycle 1 Day 15
measure: Phase I: Describe pharmacodynamics of study drugs
timeFrame: Cycle 1 (each cycle is 28 days) Days 1,8,15 and 22 and Day 1 of subsequent cycles
measure: Phase I: Radiographic tumor response based on Prostate Cancer Working Group 3 (PCWG3)
timeFrame: At the end of each 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment
measure: Phase I: Radiographic tumor response based on RECIST 1.1
timeFrame: At the end of each 28 day treatment cycle for cycles 2,4 and 6 and then every 3 cycles after cycle 6 and within 15 days of last treatment
Other outcomes:
measure: Phase I: Relationship between PSA levels and testosterone levels
timeFrame: Cycle 1 (each cycle is 28 days) Days 1,8,15 and 22 and Day 1 of subsequent cycles
measure: Phase I: Explore correlation between anti-tumor activity and patient's PTEN status
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
measure: Phase I: Explore correlation between anti-tumor activity and patient's BRCA mutation status
timeFrame: At the end of each 28 day treatment cycle and within 15 days of last treatment
Locations:
city: Tucson
country: United States
facility: Urological Associates of Southern Arizona
state: Arizona
city: Encinitas
country: United States
facility: California Cancer Associates for Researh & Excellence, Inc
state: California
city: Norwich
country: United States
facility: Eastern Connnecticut Hematology/Oncology Associates
state: Connecticut
city: Columbus
country: United States
facility: Piedmont Columbus Regional Research Institute
state: Georgia
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Topeka
country: United States
facility: Cotton-O'Neil Clinical Research Center
state: Kansas
city: Syracuse
country: United States
facility: Associated Medical Professionals of NY
state: New York
city: Florence
country: United States
facility: Oregon Urology Institute
state: Oregon
city: Greenville
country: United States
facility: Greenville Hospital System
state: South Carolina
city: Dallas
country: United States
facility: Mary Crowley Cancer Research Centers
state: Texas
city: Temple
country: United States
facility: Baylor Scott and White Health
state: Texas
city: Tacoma
country: United States
facility: Northwest Medical Specialties, PLLC
state: Washington
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center
state: Gyeonggido
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyunggido
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Laekna Therapeutics
name: Yong Yue, MD
role: STUDY_CHAIR
References: